A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record. Questions here cover its trial design and its supply landscape.
My background is chemistry rather than physiology, which may explain where I am stuck. These are treated as interchangeable and I do not think they are. If both are…
What I have: SURPASS-3 · dulaglutide. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
Concretely: 40 mg · oral semaglutide. I want to know whether this is a real physical effect or an artefact of how it is measured. What prompted the question is an…
Every comparison I find is either a marketing graphic putting -20.9% next to -14.9% with no caveats, or a methodology piece telling me cross-trial comparison is…
I have photographs before and after reconstitution if the visual detail matters. I keep seeing this stated as a fact with no explanation attached, and unexplained…
The obesity pipeline is currently full of phase 2 results being quoted as though they were established magnitudes. Retatrutide at -24.2% over 48 weeks is the…
Stated plainly: SURMOUNT-5 · a GLP-1 receptor agonist. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
Numbers first: 30 mg · orforglipron. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how confident…
The case in front of me: SURMOUNT-4 · tirzepatide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a…
Details up front: PIONEER-4 · dulaglutide. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…
For reference: 50 mg · survodutide. I would like the mechanism, because I want to be able to reason about the cases nobody has written about. I have tried to reason…
The specifics, since they change the answer: PIONEER-4 · ecnoglutide. I want to understand what this actually establishes, as opposed to what it is being used to…
Setup, so nobody has to ask: STEP 1 · mazdutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
The clinician who ordered the panel was not concerned; I would still like to understand it. This is one of those things that everyone repeats and nobody derives. This…
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse results